Muhdo partner with NUS in advanced longevity research

Singapore

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

National University of Singapore and Muhdo Heath set to collaborate on an advanced global research project on longevity analysing epigenetic change.

Muhdo Health announced today it is joining forces with the National University of Singapore (NUS) and Professor Brian Kennedy to bring about one the most advanced research projects focused on healthy aging and longevity ever undertaken. The research will take place on a global scale, involving the analysis of epigenetic changes on the human body. The study will focus on the changes that occur during aging and the effects that lifestyle and environment have on gene expression.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE